treatment

Dr. Abdulraheem Yacoub talks with Leigh Clark about MDS-MPN overlap. He includes how molecular testing is used in determining treatment options.
He also discusses the newly approved drug, Luspatercept, for the treatment of MDS and MDS-MPN overlap syndromes.

Here is a discussion of the recent approval of Luspatercept with Dr. Amit Verma, Director of the Division of Hematologic Malignancies and a Professor of Oncology at the Albert Einstein College of Medicine in New York City. He explains the results of clinical trials and describes which MDS patients have the best response to this medication.

 #MDS #treatingMDS

Dr. Gustavo Rivero describes strategies for the management of Low-Risk MDS, or Myelodysplastic Syndromes. He details supportive care for these patients, including transfusions and iron overload therapies.

Dr Vu Duong explains risk classifications for MDS. He dives into IPSS and IPSS-R scores, focused on helping patients to understand the meanings of high-risk and low-risk MDS.

Dr. Tiffany Tanaka from the University of California, San Diego explains the development of High-Risk MDS into AML. She talks about new diagnostic and treatment regimens for these patients.